To evaluate the incidence of septic shock in patients receiving biomarker-guided immunotherapy compared to placebo in the ImmunoSep trial, highlighting the significance of these findings for clinical practice.
Key Findings:
Septic shock occurred in 22.1% of 131 patients receiving immunotherapy versus 11.7% of 145 in the placebo group.
Crude odds ratio for septic shock was 2.1 (95% CI, 1.1–4.1).
In macrophage activation–like syndrome, 28.0% of 25 receiving anakinra developed septic shock versus 13.0% of 23 in placebo.
In sepsis-induced immunoparalysis, 20.8% of 106 receiving interferon-γ developed septic shock versus 11.5% of 122 in placebo.
Interpretation:
The increased incidence of septic shock may be influenced by underlying disease processes or treatment-related immune responses, and findings should be viewed as exploratory rather than definitive, with implications for clinical practice.
Limitations:
Small number of events leading to fragile statistical differences, impacting the reliability of results.
Secondary safety outcomes lack the inferential weight of primary endpoints.
Descriptive nature of safety analyses increases chance findings.
Conclusion:
Septic shock represents a significant clinical concern in ICU settings, and further analysis is needed to clarify the relationship between immunotherapy and septic shock incidence, emphasizing the need for additional research.
